Corbus Pharmaceuticals Holdings Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Corbus Pharmaceuticals Holdings de winst en omzet met respectievelijk 5.1% en 76.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 20.6% per jaar.

Belangrijke informatie

5.1%

Groei van de winst

20.65%

Groei van de winst per aandeel

Biotechs winstgroei	25.4%
Inkomstengroei	76.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	17 Jun 2026

Recente toekomstige groei-updates

Recent updates

Analyseartikel • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha

Analyseartikel • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analyseartikel • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...

Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Winst- en omzetgroeiprognoses

NasdaqCM:CRBP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	3	-164	-143	-147	9
12/31/2027	2	-123	-106	-103	9
12/31/2026	1	-98	-96	-68	9
3/31/2026	N/A	-85	-74	-74	N/A
12/31/2025	N/A	-79	-64	-64	N/A
9/30/2025	N/A	-68	-60	-60	N/A
6/30/2025	N/A	-58	-58	-58	N/A
3/31/2025	N/A	-50	-50	-50	N/A
12/31/2024	N/A	-40	-42	-42	N/A
9/30/2024	N/A	-39	-37	-37	N/A
6/30/2024	N/A	-35	-30	-30	N/A
3/31/2024	N/A	-34	-29	-29	N/A
12/31/2023	N/A	-45	-36	-36	N/A
9/30/2023	N/A	-47	-38	-38	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-51	-42	-42	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-42	-40	-40	N/A
6/30/2022	0	-35	-32	-32	N/A
3/31/2022	0	-39	-37	-37	N/A
12/31/2021	1	-46	-48	-48	N/A
9/30/2021	2	-44	-57	-57	N/A
6/30/2021	3	-77	-85	-85	N/A
3/31/2021	3	-98	-94	-94	N/A
12/31/2020	4	-111	-100	-100	N/A
9/30/2020	6	-129	-106	-104	N/A
6/30/2020	7	-115	-97	-94	N/A
3/31/2020	36	-75	-87	-84	N/A
12/31/2019	36	-71	N/A	-46	N/A
9/30/2019	35	-62	N/A	-37	N/A
6/30/2019	34	-56	N/A	-29	N/A
3/31/2019	6	-70	N/A	-18	N/A
12/31/2018	5	-56	N/A	-30	N/A
9/30/2018	3	-49	N/A	-25	N/A
6/30/2018	3	-41	N/A	-23	N/A
3/31/2018	2	-37	N/A	-23	N/A
12/31/2017	2	-32	N/A	-28	N/A
9/30/2017	3	-29	N/A	-24	N/A
6/30/2017	3	-28	N/A	-21	N/A
3/31/2017	3	-25	N/A	-18	N/A
12/31/2016	2	-20	N/A	-14	N/A
9/30/2016	2	-15	N/A	-9	N/A
6/30/2016	1	-12	N/A	-8	N/A
3/31/2016	1	-10	N/A	-6	N/A
12/31/2015	1	-9	N/A	-5	N/A
9/30/2015	0	-8	N/A	-5	N/A
6/30/2015	0	-6	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CRBP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CRBP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CRBP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CRBP ( 76.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 13% per jaar).

Hoge groei-inkomsten: De omzet van CRBP ( 76.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CRBP naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/20 20:49
Aandelenkoers aan het einde van de dag	2026/06/18 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Corbus Pharmaceuticals Holdings, Inc. wordt gevolgd door 22 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Kalpit Patel	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.

Corbus Pharmaceuticals Holdings Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 7.4% to US$39.00

Price target increased by 8.2% to US$44.00

Price target decreased by 7.2% to US$42.89

Consensus EPS estimates upgraded to US$4.32 loss

Price target decreased by 9.9% to US$56.78

Price target decreased by 13% to US$71.00

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

New minor risk - Share price stability

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Price target decreased by 7.4% to US$39.00

Corbus Pharmaceuticals Holdings, Inc. Announces Updated Clinical Data for CRB-701 At ASCO 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Chief Medical Officer Dr. Dominic Smethurst, Effective June 30, 2026

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 13, 2026

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025

Corbus Pharmaceuticals Holdings, Inc. Reports Results from Phase 1A Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

New major risk - Shareholder dilution

Price target increased by 8.2% to US$44.00

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $74.999901 million.

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025

Corbus Pharmaceuticals Holdings, Inc. to Host In-Person and Virtual KOL Event At ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB -701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Its Nectin-4 Targeting Adc CRB -701 At the 2025 ESMO Annual Congress

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Corbus Pharmaceuticals Holdings Inc. Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell 3000E Value Index

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed with Its Nectin-4 Targeting ADC CRB-701 in Combination with Keytruda (Pembrolizumab)

Price target decreased by 7.2% to US$42.89

Corbus Pharmaceuticals Holdings, Inc. Announces Board Changes, Effective May 15, 2025

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 15, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

Peter Salzmann Not to Stand for Re-Election as Director of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Appoints Ian Hodgson as Chief Operating Officer

Consensus EPS estimates upgraded to US$4.32 loss

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Price target decreased by 9.9% to US$56.78

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability